These data suggest that CREB/ATF1 activation may antagonize the anti-cancer effect of aspirin, and targeting CREB/ATF1 may be a strategy to sensitize HCC cells to aspirin. The gene discussed is CREB1; the disease is hepatocellular carcinoma.